For decades, GLP-1 weight-loss drugs cost around $1,300 a month out of pocket — a price that made them, in practice, a luxury good. Starting July 1, Medicare’s GLP-1 Bridge program lets eligible beneficiaries access them for under $50. That’s not a discount. It’s a payer change, and payer changes create entirely new markets.
History has a clean parallel. In 18th-century Prussia, potatoes were initially seen as food for the poor — until Frederick the Great, wanting to push adoption, allegedly had royal potato fields guarded so peasants would assume they were valuable enough to steal. Scarcity and price signal status; once a good becomes affordable and accessible, the population that “owns” it flips. Obesity itself followed this arc — once a marker of wealth in eras of food scarcity, now disproportionately concentrated among lower-income groups in food-abundant economies.
GLP-1 drugs are tracing the same line in reverse. At $1,300, the buyer pool was small and self-selected — wealthy, motivated, paying directly. At under $50, the buyer pool becomes Medicare’s roughly 45 million beneficiaries, and the prescribing incentive structure changes too: physicians, pharmacies, and manufacturers are now operating inside a reimbursement system built for volume, not one-off purchases. That’s what “recurring, predictable revenue” actually looks like at the pipeline stage — not a pricing strategy, but a structural shift in who’s allowed to buy.
For investors, the lesson isn’t about this drug class specifically. It’s that market size is rarely a function of the sticker price — it’s a function of who’s paying. A company sitting on a pipeline asset waiting for this kind of payer expansion isn’t betting on demand. It’s betting on access.
The Dollar Tree Diet.
Not advice. Just how I see it.